bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2021-66-3-445-457bloodjour-306Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSКрупноклеточная В-клеточная лимфома с перестройкой IRF4Large B-cell lymphoma with IRF4 rearrangementhttps://orcid.org/0000-0001-5396-2113ПластининаЛ. В.PlastininaL. V.

 Пластинина Любовь Васильевна*, кандидат медицинских наук, гематолог консультативного гематологического отделения с дневным стационаром по проведению интенсивной высокодозной химиотерапии

 125167, Москва 

 Liubov V. Plastinina*, Cand. Sci. (Med.), Hematologist, Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy 

 125167, Moscow 

dr.plastinina@yandex.ruhttps://orcid.org/0000-0001-9591-8508МоисееваТ. Н.MoiseevaT. N.

 Моисеева Татьяна Николаевна, кандидат медицинских наук, гематолог, заведующая консультативным гематологическим отделением с дневным стационаром по проведению интенсивной высокодозной химиотерапии

 125167, Москва 

 Tatiana N. Moiseeva, Cand. Sci. (Med.), Head of the Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy 

 125167, Moscow 

moiseeva.t@blood.ruhttps://orcid.org/0000-0002-6702-9575Аль-РадиЛ. С.Al-RadiL. S.

 Аль-Ради Любовь Саттаровна, кандидат медицинских наук, врач-гематолог консультативного гематологического отделения с дневным стационаром по проведению интенсивной высокодозной химиотерапии

 125167, Москва 

 Liubov S. Al-Radi, Cand. Sci. (Med.), Hematologist, Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy 

 125167, Moscow 

alradi.l@blood.ruhttps://orcid.org/0000-0002-1082-8659КовригинаА. М.KovriginaA. M.

 Ковригина Алла Михайловна, доктор биологических наук, заведующая патологоанатомическим отделением

125167, Москва

 Alla M. Kovrigina, Dr. Sci. (Biol.), Pathologist, Head of the Pathology Department 

 125167, Moscow 

kovrigina.a@blood.ruhttps://orcid.org/0000-0003-1613-652XОбуховаТ. Н.ObukhovaT. N.

 Обухова Татьяна Никифоровна, кандидат медицинских наук, заведующая лабораторией кариологии

 125167, Москва 

 Tatiana N. Obukhova, Cand. Sci. (Med.), Head of the Karyology Laboratory 

 125167, Moscow 

obukhova.t@blood.ruhttps://orcid.org/0000-0003-3906-9171ГорячеваС. Р.GoryachevaS. R.

 Горячева Светлана Рудольфовна, кандидат медицинских наук, гематолог консультативного гематологического отделения с дневным стационаром по проведению интенсивной высокодозной химиотерапии

 125167, Москва 

 Svetlana R. Goryacheva, Cand. Sci. (Med.), Hematologist, Consultative Hematology Department with a Day Hospital for Intensive High-Dose Chemotherapy 

 125167, Moscow 

goryacheva.s@blood.ruhttps://orcid.org/0000-0003-0922-9314ШуплецоваИ. А.ShupletsovaI. A.

 Шуплецова Ирина Александровна, кандидат медицинских наук, врач патологоанатомического отделения

 125167, Москва 

 Irina A. Shupletsova, Cand. Sci. (Med.), Pathologist, Pathology Department 

 125167, Moscow 

shupletsova.i@blood.ruhttps://orcid.org/0000-0003-4263-8275МагомедоваА. У.MagomedovaA. U.

 Магомедова Аминат Умарасхабовна, доктор медицинских наук, ведущий научный сотрудник отделения интенсивной высокодозной химиотерапии гемобластозов

 125167, Москва 

 Aminat U. Magomedova, Dr. Sci. (Med.), Lead Researcher, Department of Intensive High-Dose Chemotherapy of Haemoblastosis 

 125167, Moscow 

magomedova.a@blood.ruhttps://orcid.org/0000-0002-7721-2074КравченкоС. К.KravchenkoS. K.

 Кравченко Сергей Кириллович, кандидат медицинских наук, заведующий отделением интенсивной высокодозной химиотерапии гемобластозов

 125167, Москва 

 Sergey K. Kravchenko, Cand. Sci. (Med.), Head of the Department of Intensive High-Dose Chemotherapy of Haemoblastosis 

 125167, Moscow 

kravchenko.s@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation202125102021663445457Copyright © Пластинина Л.В., Моисеева Т.Н., Аль-Ради Л.С., Ковригина А.М., Обухова Т.Н., Горячева С.Р., Шуплецова И.А., Магомедова А.У., Кравченко С.К., 20212021Пластинина Л.В., Моисеева Т.Н., Аль-Ради Л.С., Ковригина А.М., Обухова Т.Н., Горячева С.Р., Шуплецова И.А., Магомедова А.У., Кравченко С.К.Plastinina L.V., Moiseeva T.N., Al-Radi L.S., Kovrigina A.M., Obukhova T.N., Goryacheva S.R., Shupletsova I.A., Magomedova A.U., Kravchenko S.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/306Введение

Введение. Крупноклеточная В-клеточная лимфома с перестройкой IRF4 — редкая патология, возникает у детей и молодых взрослых, протекает с вовлечением лимфатических узлов головы, шеи и/или лимфоидного кольца Пирогова — Вальдейера. Особенностью опухоли является экспрессия белка MUM1 c перестройкой гена IRF4/6p25.3.

Цель — представить клиническое наблюдение крупноклеточной В-клеточной лимфомы с перестройкой IRF4.

Основные данные

Основные данные. Представлено наблюдение за больным IRF4-позитивной крупноклеточной В-клеточной лимфомой. Диагноз установлен на основании морфологического, иммуногистохимического, цитогенетического исследований, флуоресцентной гибридизации in situ и клинических проявлений. Особенностью случая явился преимущественно диффузный характер роста крупных опухолевых клеток в биоптате лимфатического узла в сочетании с индолентным клиническим течением заболевания, а также наличие цитогенетических аберраций обоих гомологов хромосомы 6: перестройки IRF4 и делеции 6p25. Проведение четырех курсов R-CHOP-21 позволило достичь ремиссии заболевания, сохраняющейся в течение 26 мес.

Introduction

Introduction. Large B-cell lymphoma with IRF4 rearrangement is rare disease, recently described in WHO 2017, arising in children and young adults, presenting with enlarged lymph nodes of the head and neck and/or Waldeyer ring. It is characterized by strong expression of MUM1 protein with IRF4 rearrangement.

Aim — to present a clinical case of large B-cell lymphoma with IRF4 rearrangement and characterize its clinical, morphological, and cytogenetic features.

Main findings

Main findings. An observation of a patient with a rare case of large B-cell lymphoma with IRF4 rearrangement is presented.

In-depth morphological, immunohistochemical analysis, and additional research methods made it possible to establish a correct diagnosis. Features of the case were the predominantly diffuse growth of large tumor cells in the lymph node biopsy with the indolent clinical course, and the presence of aberrations in both homologues of chromosome 6: IRF4 rearrangement and deletion 6p25. Treatment with 4 R-CHOP-21 courses allowed for the achievement of disease remission, which continued 26 months post treatment.

крупноклеточная В-клеточная лимфомаIRF4IRF4-позитивная лимфомаморфологияиммуногистохимияфлуоресцентная гибридизация in sitularge B-cell lymphoma with IRF4 rearrangementIRF4-positive lymphomamorphologyimmunohistochemistryfl uorescence hybridization in situReferencesPittaluga S., Harris N., Siebert R., et al. Large B-cell lymphoma with IRF4 rearrangement. In: Swerdlow S.H., Campo E.H.N. (Eds). WHO Classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2017: 280–1.Pittaluga S., Harris N., Siebert R., et al. Large B-cell lymphoma with IRF4 rearrangement. In: Swerdlow S.H., Campo E.H.N. (Eds). WHO Classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2017: 280–1.Tanaka N., Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol. 2000; 10(2): 73–81. DOI: 10.1006/scbi.2000.0310.Tanaka N., Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol. 2000; 10(2): 73–81. DOI: 10.1006/scbi.2000.0310.Grossman A., Mittrücker H.W., Nicholl J., et al. Cloning of human lymphocyte-specifi c interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. Genomics. 1996; 37(2): 229–33. DOI: 10.1006/geno.1996.0547.Grossman A., Mittrücker H.W., Nicholl J., et al. Cloning of human lymphocyte-specifi c interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. Genomics. 1996; 37(2): 229–33. DOI: 10.1006/geno.1996.0547.Iida S., Rao P.H., Butler M., et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17(2): 226–30. DOI: 10.1038/ng1097-226.Iida S., Rao P.H., Butler M., et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17(2): 226–30. DOI: 10.1038/ng1097-226.Yoshida S., Nakazawa N., Iida S., et al. Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999; 13(11): 1812–6. DOI: 10.1038/sj.leu.2401563.Yoshida S., Nakazawa N., Iida S., et al. Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999; 13(11): 1812–6. DOI: 10.1038/sj.leu.2401563.Mittrücker H.W., Matsuyama T., Grossman A., et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. J Immunol. 2017; 199(11): 3717–20. DOI: 10.1126/science.275.5299.540.Mittrücker H.W., Matsuyama T., Grossman A., et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. J Immunol. 2017; 199(11): 3717–20. DOI: 10.1126/science.275.5299.540.Saito T., Yamagata T., Takahashi T., et al. ICSAT overexpression is not suffi cient to cause adult T-cell leukemia or multiple myeloma. Biochem Biophys Res Commun. 1999; 260(2): 329–31. DOI: 10.1006/bbrc.1999.0911.Saito T., Yamagata T., Takahashi T., et al. ICSAT overexpression is not suffi cient to cause adult T-cell leukemia or multiple myeloma. Biochem Biophys Res Commun. 1999; 260(2): 329–31. DOI: 10.1006/bbrc.1999.0911.Grumont R.J., Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: Modulation of interferon-regulated gene expression by Rel/nuclear factor B. J Exp Med. 2000; 191(8): 1281–91. DOI: 10.1084/jem.191.8.1281.Grumont R.J., Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: Modulation of interferon-regulated gene expression by Rel/nuclear factor B. J Exp Med. 2000; 191(8): 1281–91. DOI: 10.1084/jem.191.8.1281.Shaffer A.L., Wright G., Yang L., et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006; 210(1): 67–85. DOI: 10.1111/j.0105-2896.2006.00373.x.Shaffer A.L., Wright G., Yang L., et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006; 210(1): 67–85. DOI: 10.1111/j.0105-2896.2006.00373.x.Falini B., Fizzotti M., Pucciarini A., et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000; 95(6): 2084–92.Falini B., Fizzotti M., Pucciarini A., et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000; 95(6): 2084–92.Martinez A., Pittaluga S., Rudelius M., et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: A novel germinal center marker. Am J Surg Pathol. 2008; 32(8): 1190–200. DOI: 10.1097/PAS.0b013e318166f46a.Martinez A., Pittaluga S., Rudelius M., et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: A novel germinal center marker. Am J Surg Pathol. 2008; 32(8): 1190–200. DOI: 10.1097/PAS.0b013e318166f46a.Gualco G., Weiss L., Bacchi C. MUM1/IRF4: A review. Appl Immunohistochem Mol Morphol AIMM. 2010; 18(4): 301–10. DOI: 10.1097/PAI.0B013E3181CF1126.Gualco G., Weiss L., Bacchi C. MUM1/IRF4: A review. Appl Immunohistochem Mol Morphol AIMM. 2010; 18(4): 301–10. DOI: 10.1097/PAI.0B013E3181CF1126.Satou A., Asano N., Kato S., et al. Prognostic impact of MUM1/IRF4 expression in Burkitt Lymphoma (BL): A reappraisal of 88 BL patients in Japan. Am J Surg Pathol. 2017; 41(3): 389–95. DOI: 10.1097/PAS.0000000000000804.Satou A., Asano N., Kato S., et al. Prognostic impact of MUM1/IRF4 expression in Burkitt Lymphoma (BL): A reappraisal of 88 BL patients in Japan. Am J Surg Pathol. 2017; 41(3): 389–95. DOI: 10.1097/PAS.0000000000000804.Valsami S., Pappa V., Rontogianni D., et al. A clinicopathological study of Bcell differentiation markers and transcription factors in classical Hodgkin’s lymphoma: A potential prognostic role of MUM1/IRF4. Haematologica. 2007; 92(10):1343–50. DOI: 10.3324/haematol.11523.Valsami S., Pappa V., Rontogianni D., et al. A clinicopathological study of Bcell differentiation markers and transcription factors in classical Hodgkin’s lymphoma: A potential prognostic role of MUM1/IRF4. Haematologica. 2007; 92(10):1343–50. DOI: 10.3324/haematol.11523.Xerri L., Bachy E., Fabiani B., et al. Identifi cation of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. Hum Pathol. 2014; 45(10): 2085–93. DOI: 10.1016/j.humpath.2014.06.019.Xerri L., Bachy E., Fabiani B., et al. Identifi cation of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. Hum Pathol. 2014; 45(10): 2085–93. DOI: 10.1016/j.humpath.2014.06.019.Kridel R., Mottok A., Farinha P., et al. Cell-of-origin of transformed follicular lymphoma. Blood. 2015; 126(18): 2118–27. DOI: 10.1182/blood-2015-06-649905.Kridel R., Mottok A., Farinha P., et al. Cell-of-origin of transformed follicular lymphoma. Blood. 2015; 126(18): 2118–27. DOI: 10.1182/blood-2015-06-649905.Salaverria I., Philipp C., Oschlies I., et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011; 118(1): 139–47. DOI: 10.1182/blood-2011-01-330795.Salaverria I., Philipp C., Oschlies I., et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011; 118(1): 139–47. DOI: 10.1182/blood-2011-01-330795.Takeuchi K., Sakata S., Asaka R., et al. A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement. Haematologica. 2013; 98(3): e32–5. DOI: 10.3324/haematol.2012.076851.Takeuchi K., Sakata S., Asaka R., et al. A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement. Haematologica. 2013; 98(3): e32–5. DOI: 10.3324/haematol.2012.076851.Tamura A., Miura I., Iida S., et al. Interphase detection of immunoglobulin heavy chain gene translocations with specifi c oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet. 2001; 129(1): 1–9. DOI: 10.1016/s0165-4608(01)00436-8.Tamura A., Miura I., Iida S., et al. Interphase detection of immunoglobulin heavy chain gene translocations with specifi c oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet. 2001; 129(1): 1–9. DOI: 10.1016/s0165-4608(01)00436-8.Hunt K.E., Hall B., Reichard K.K. Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2010;18(2): 109–12. DOI: 10.1097/PAI.0b013e31817fa43c.Hunt K.E., Hall B., Reichard K.K. Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2010;18(2): 109–12. DOI: 10.1097/PAI.0b013e31817fa43c.Ramis-Zaldivar J.E., Gonzalez-Farré B., Balagué O., et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020; 135(4): 274–86. DOI: 10.1182/blood.2019002699.Ramis-Zaldivar J.E., Gonzalez-Farré B., Balagué O., et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020; 135(4): 274–86. DOI: 10.1182/blood.2019002699.Salaverria I., Martin-Guerrero I., Burkhardt B., et al. High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. Genes Chromosom Cancer. 2013; 52(2): 150–5. DOI: 10.1002/gcc.22014.Salaverria I., Martin-Guerrero I., Burkhardt B., et al. High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. Genes Chromosom Cancer. 2013; 52(2): 150–5. DOI: 10.1002/gcc.22014.Level L. De, Bonnet C., Copie-Bergman C., et al. Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: A GELA study. Ann Oncol. 2012; 23(12): 3143–51. DOI: 10.1093/annonc/mds150.Level L. De, Bonnet C., Copie-Bergman C., et al. Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: A GELA study. Ann Oncol. 2012; 23(12): 3143–51. DOI: 10.1093/annonc/mds150.Liu Q., Salaverria I., Pittaluga S., et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013; 37(3): 333–43. DOI: 10.1038/jid.2014.371.Liu Q., Salaverria I., Pittaluga S., et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013; 37(3): 333–43. DOI: 10.1038/jid.2014.371.Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin’s disease staging classifi cation. Cancer Res. 1971; 31(11): 1860–1.Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin’s disease staging classifi cation. Cancer Res. 1971; 31(11): 1860–1.Chisholm K.M., Termuhlen A., Perkins S.L., et al. IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children’s Oncology Group trials. Pediatr Blood Cancer. 2019; 66(8): e27770. DOI: 10.1002/pbc.27770.Chisholm K.M., Termuhlen A., Perkins S.L., et al. IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children’s Oncology Group trials. Pediatr Blood Cancer. 2019; 66(8): e27770. DOI: 10.1002/pbc.27770.Verma A., Epari S., Gujral S., et al. An unusual presentation of large B-cell lymphoma with interferon regulatory factor 4 gene rearrangement. Indian J Pathol Microbiol. 2018; 61(2): 271–4. DOI: 10.4103/IJPM.IJPM_194_17.Verma A., Epari S., Gujral S., et al. An unusual presentation of large B-cell lymphoma with interferon regulatory factor 4 gene rearrangement. Indian J Pathol Microbiol. 2018; 61(2): 271–4. DOI: 10.4103/IJPM.IJPM_194_17.Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confi rmation of the molecular classifi cation of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275–82. DOI: 10.1182/blood-2003-05-1545.Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confi rmation of the molecular classifi cation of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275–82. DOI: 10.1182/blood-2003-05-1545.NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.NCCN Clinical Practice Guidelines in Oncology. B-cell lymphomas. Version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.Quintanilla-Martinez L., Sander B., Chan J.K.C., et al. Indolent lymphomas in the pediatric population: Follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch. 2016; 468(2): 141–57. DOI: 10.1007/s00428-015-1855-z.Quintanilla-Martinez L., Sander B., Chan J.K.C., et al. Indolent lymphomas in the pediatric population: Follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch. 2016; 468(2): 141–57. DOI: 10.1007/s00428-015-1855-z.Man J., Wang Y., Zhai X., et al. Large B-cell lymphoma with IRF4 rearrangement: A special tonsillar lymphoma in children. Pediatr Hematol Oncol J. 2019; 4(4): 77–81. DOI: 10.1016/j.phoj.2019.12.001.Man J., Wang Y., Zhai X., et al. Large B-cell lymphoma with IRF4 rearrangement: A special tonsillar lymphoma in children. Pediatr Hematol Oncol J. 2019; 4(4): 77–81. DOI: 10.1016/j.phoj.2019.12.001.Chonabayashi K., Tamori S., Taniwaki M., et al. Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion. Ann Hematol. 2014; 93(5): 893–4. DOI: 10.1007/s00277-013-1889-8.Chonabayashi K., Tamori S., Taniwaki M., et al. Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion. Ann Hematol. 2014; 93(5): 893–4. DOI: 10.1007/s00277-013-1889-8.Vincent G., Richebourg S., Cloutier S., et al. Large B-cell lymphoma with IRF4 rearrangement: From theory to practice. AJSP Rev Reports. 2019; 24(5): 240. DOI: 10.1097/PCR.0000000000000329.Vincent G., Richebourg S., Cloutier S., et al. Large B-cell lymphoma with IRF4 rearrangement: From theory to practice. AJSP Rev Reports. 2019; 24(5): 240. DOI: 10.1097/PCR.0000000000000329.Yu Y.T., Sakata S., Takeuchi K., et al. Tonsillar follicular large B-cell lymphoma with IRF4 rearrangement causing sleep apnoea. J Clin Pathol. 2020; 73(2): 120–1. DOI: 10.1136/jclinpath-2019-205915.Yu Y.T., Sakata S., Takeuchi K., et al. Tonsillar follicular large B-cell lymphoma with IRF4 rearrangement causing sleep apnoea. J Clin Pathol. 2020; 73(2): 120–1. DOI: 10.1136/jclinpath-2019-205915.Ma Z., Shi Y., Pang X., et al. Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma. Medicine (Baltomore). 2020; 99(2): e18670. DOI: 10.1097/MD.0000000000018670.Ma Z., Shi Y., Pang X., et al. Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma. Medicine (Baltomore). 2020; 99(2): e18670. DOI: 10.1097/MD.0000000000018670.Nasim M.M., Chalif D.J., Demopoulos A.M., et al. Primary low-grade B-cell lymphoma of skull with translocation between immunoglobulin and interferon regulatory factor 4 genes. Int J Surg Pathol. 2020; 28(3): 330–5. DOI: 10.1177/1066896919883013.Nasim M.M., Chalif D.J., Demopoulos A.M., et al. Primary low-grade B-cell lymphoma of skull with translocation between immunoglobulin and interferon regulatory factor 4 genes. Int J Surg Pathol. 2020; 28(3): 330–5. DOI: 10.1177/1066896919883013.

The authors declare that there are no conflicts of interest present.